Q3 EPS Estimates for Kodiak Sciences Lifted by HC Wainwright

Kodiak Sciences Inc. (NASDAQ:KOD) – HC Wainwright boosted their Q3 2025 earnings per share estimates for Kodiak Sciences in a report issued on Tuesday, November 11th. HC Wainwright analyst M. Caufield now forecasts that the company will post earnings of ($1.04) per share for the quarter, up from their prior forecast of ($1.05). HC Wainwright currently has a “Buy” rating and a $24.00 price target on the stock. The consensus estimate for Kodiak Sciences’ current full-year earnings is ($3.45) per share. HC Wainwright also issued estimates for Kodiak Sciences’ Q4 2025 earnings at ($0.95) EPS, FY2025 earnings at ($4.10) EPS, Q1 2026 earnings at ($0.63) EPS, Q2 2026 earnings at ($0.65) EPS, Q3 2026 earnings at ($0.71) EPS, Q4 2026 earnings at ($0.77) EPS and FY2026 earnings at ($2.76) EPS.

Other analysts have also recently issued research reports about the stock. JPMorgan Chase & Co. upgraded shares of Kodiak Sciences from a “neutral” rating to an “overweight” rating and raised their price objective for the company from $15.00 to $24.00 in a research note on Friday, October 24th. Jefferies Financial Group started coverage on shares of Kodiak Sciences in a report on Monday, September 22nd. They issued a “buy” rating and a $15.00 target price for the company. Lifesci Capital assumed coverage on Kodiak Sciences in a research note on Thursday, October 23rd. They set an “outperform” rating and a $40.00 price target on the stock. Chardan Capital restated a “neutral” rating and issued a $14.00 price target on shares of Kodiak Sciences in a report on Monday, October 6th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Kodiak Sciences in a research note on Wednesday, October 8th. Four analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Kodiak Sciences currently has a consensus rating of “Hold” and an average price target of $22.33.

Kodiak Sciences Stock Performance

Shares of NASDAQ KOD opened at $20.25 on Thursday. Kodiak Sciences has a one year low of $1.92 and a one year high of $21.17. The firm has a market capitalization of $1.07 billion, a P/E ratio of -5.33 and a beta of 2.88. The company’s fifty day moving average is $14.76 and its two-hundred day moving average is $8.79.

Kodiak Sciences (NASDAQ:KOD) last released its earnings results on Wednesday, August 13th. The company reported ($1.03) EPS for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.02).

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Adage Capital Partners GP L.L.C. lifted its stake in Kodiak Sciences by 55.1% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 2,055,707 shares of the company’s stock valued at $7,668,000 after buying an additional 730,000 shares in the last quarter. Acadian Asset Management LLC raised its holdings in shares of Kodiak Sciences by 1.2% in the second quarter. Acadian Asset Management LLC now owns 1,969,876 shares of the company’s stock worth $7,343,000 after acquiring an additional 23,742 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Kodiak Sciences by 7.0% in the third quarter. Vanguard Group Inc. now owns 1,950,292 shares of the company’s stock worth $31,926,000 after acquiring an additional 127,991 shares during the last quarter. ICONIQ Capital LLC lifted its position in shares of Kodiak Sciences by 24.6% in the first quarter. ICONIQ Capital LLC now owns 1,266,563 shares of the company’s stock valued at $3,559,000 after acquiring an additional 249,699 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. boosted its stake in shares of Kodiak Sciences by 90.1% during the first quarter. Jacobs Levy Equity Management Inc. now owns 685,198 shares of the company’s stock valued at $1,922,000 after acquiring an additional 324,722 shares during the last quarter. 89.06% of the stock is currently owned by institutional investors and hedge funds.

Kodiak Sciences Company Profile

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.